Bruce G. Allen Investments LLC Has $54,000 Position in Pfizer Inc. (NYSE:PFE)

Bruce G. Allen Investments LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 33.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,133 shares of the biopharmaceutical company’s stock after selling 1,073 shares during the period. Bruce G. Allen Investments LLC’s holdings in Pfizer were worth $54,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in PFE. Rialto Wealth Management LLC acquired a new position in Pfizer during the fourth quarter worth approximately $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $27,000. Gould Capital LLC boosted its holdings in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the fourth quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer in the fourth quarter valued at approximately $30,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective for the company. UBS Group boosted their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Citigroup reissued a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Stock Performance

Shares of PFE stock opened at $23.36 on Monday. The firm has a market cap of $132.81 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The stock’s 50-day moving average is $22.95 and its two-hundred day moving average is $25.00. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same period in the prior year, the company posted $0.82 earnings per share. The firm’s revenue for the quarter was down 7.8% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.36%. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.